# Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma

> **NCT02329717** · PHASE2 · UNKNOWN · sponsor: **Phoenix Biotechnology, Inc** · enrollment: 50 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** PBI 05204

## Key facts

- **NCT ID:** NCT02329717
- **Lead sponsor:** Phoenix Biotechnology, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2016-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02329717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02329717, "Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02329717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*